依折麦布对非酒精性脂肪性肝病（NAFLD）的疗效

[The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD)].

作者信息

Shiwa Tadashi, Kawanami Yoshiya, Yokoyama Tomoko, Moritani Akihiko, Hashimoto Masatoshi, Gotoh Tohru

机构信息

Department of Internal Medicine, Fuji Film Health Care Center.

出版信息

Nihon Shokakibyo Gakkai Zasshi. 2011 Aug;108(8):1383-92.

PMID:21817841

Abstract

The usefulness of ezetimibe was examined in 297 patients with dyslipidemia who did not achieve LDL-C target levels set in JAS 2007 Guidelines by lifestyle modification. The mean period of administration was 178.2±295.4 days. Ezetimibe significantly improved serum lipid levels in the patients with and without non-alcoholic fatty liver disease (NAFLD) (p<0.01). Significant improvement of AST, ALT and γ GTP levels were also observed in the patients with NAFLD (p<0.01, p<0.05, and p<0.01, respectively). Seventy of the patients with NAFLD who underwent abdominal ultrasound before and after administration of ezetimibe were followed. Of those, 38.6% of the patients showed disappearance of steatosis, indicating that administration of ezetimibe is useful in patients with NAFLD.

摘要

对297例血脂异常患者进行了依折麦布的疗效研究，这些患者通过生活方式改变未达到2007年日本动脉粥样硬化防治指南设定的低密度脂蛋白胆固醇（LDL-C）目标水平。平均给药期为178.2±295.4天。依折麦布显著改善了患有和未患有非酒精性脂肪性肝病（NAFLD）患者的血脂水平（p<0.01）。在患有NAFLD的患者中也观察到天门冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）和γ-谷氨酰转移酶（γ-GTP）水平显著改善（分别为p<0.01、p<0.05和p<0.01）。对70例在依折麦布给药前后接受腹部超声检查的NAFLD患者进行了随访。其中，38.6%的患者脂肪变性消失，表明依折麦布给药对NAFLD患者有效。